Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Qi Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2120-2261; OpenAlex author ID A5100350270. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 2 papers · 2024: none · 2025: 2 papers

Papers 13

  1. SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Co-author DOI 10.1002/advs.202510071↗
  2. Epigenetic suppression of Nrf2-Slc40a1 axis induces ferroptosis and enhances immunotherapy in pancreatic cancer. Co-author DOI 10.1136/jitc-2025-013269↗
  3. Fully automated magnetic resonance imaging-based radiomics analysis for differentiating pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinom… Co-author DOI 10.1007/s00261-023-03801-8↗
  4. Non-enhanced magnetic resonance imaging-based radiomics model for the differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcino… Co-author DOI 10.3389/fonc.2023.1108545↗
  5. Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis. Co-author DOI 10.1007/s00330-022-08698-3↗
  6. Magnetic Resonance Radiomics and Machine-learning Models: An Approach for Evaluating Tumor-stroma Ratio in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2021.08.013↗
  7. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Co-author DOI 10.3389/fonc.2022.844527↗
  8. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  9. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  10. The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: A meta-analysis. Co-author DOI 10.1097/md.0000000000026673↗
  11. CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.707288↗
  12. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  13. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator sys… Co-author DOI 10.1158/1078-0432.ccr-13-2311↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yun Bian · 5 shared papers, 2021–2023 · strength 0.69
  2. Jieyu Yu · 5 shared papers, 2021–2023 · strength 0.69
  3. Chengwei Shao · 5 shared papers, 2021–2023 · strength 0.69
  4. Yudong Qiu · 4 shared papers, 2022–2025 · strength 0.56
  5. Yinghao Meng · 4 shared papers, 2021–2023 · strength 0.53
  6. Jianping Lu · 3 shared papers, 2022–2023 · strength 0.44
  7. Linxi Zhu · 3 shared papers, 2022–2025 · strength 0.43
  8. Jiatong Tang · 2 shared papers, 2025 · strength 0.38
  9. Changchang Lu · 3 shared papers, 2022 · strength 0.37
  10. Lei Wang · 3 shared papers, 2022 · strength 0.37
  11. Xin Qiu · 3 shared papers, 2022 · strength 0.37
  12. Baorui Liu · 3 shared papers, 2022 · strength 0.37
  13. Hao Cheng · 2 shared papers, 2022–2025 · strength 0.31
  14. Jianping Lu · 2 shared papers, 2021–2022 · strength 0.25
  15. Jing Li · 2 shared papers, 2021–2023 · strength 0.25
  16. Juan Du · 2 shared papers, 2022 · strength 0.25
  17. Jun Chen · 2 shared papers, 2022 · strength 0.25
  18. Hao Zhang · 2 shared papers, 2021–2022 · strength 0.24
  19. Shijin Xu · 1 shared paper, 2025 · strength 0.19
  20. Lei Wang · 1 shared paper, 2025 · strength 0.19
  21. Yixuan Zhang · 1 shared paper, 2025 · strength 0.19
  22. Xiaoping Zou · 1 shared paper, 2025 · strength 0.19
  23. Ying Lv · 1 shared paper, 2025 · strength 0.19
  24. Shu Zhang · 1 shared paper, 2025 · strength 0.19
  25. Neng Tang · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.